Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Food Effect of Orally Administered IPG11406 in Healthy Adult Participants
NCT06255834 is registered in ClinicalTrials.gov with Nanjing Immunophage Biotech Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Food Effect of Orally Administered IPG11406 in Healthy Adult Participants
- Lead sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 24, 2024
- Completion date
- December 30, 2024
- Enrollment
- 66 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.